IPO Amount: $47M
Date: Oct. 22
Range: $14 to $16
Actual price: $9.50

Scoop: Aegerion Pharmaceuticals in October announced the pricing of its initial public offering of 5 million shares of its common stock at $9.50 per share. It had been seeking a higher price, but, Seeking Alpha notes, there were no takers. The company's lead product compound, lomitapide, is a small molecule microsomal triglyceride transfer protein inhibitor, or MTP-I, being developed as an oral, once-a-day treatment for patients with severe lipid disorders.

In December 2008, the company Aegerion Pharmaceuticals gave up on its hopes for an IPO. The developer told the Wall Street Journal that "the window is closed." The IPO market, said CFO Will Lewis, "is just not available."